<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873104</url>
  </required_header>
  <id_info>
    <org_study_id>C-16-TS11</org_study_id>
    <nct_id>NCT02873104</nct_id>
  </id_info>
  <brief_title>Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction</brief_title>
  <official_title>Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the Cutera truSculpt radiofrequency device for
      circumferential reduction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate efficacy and safety of treatment with the
      Cutera truSculpt RF device for circumferential reduction in the abdominal and flank region.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Difference in circumferential measurement related to sham and therapeutic group at 12 weeks post-treatment</measure>
    <time_frame>12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject assessment of improvement for both sham group and therapeutic group at 12 weeks post-treatment.</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction level for both sham group and therapeutic group at 12 weeks post-treatment.</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject discomfort and pain levels during treatment</measure>
    <time_frame>12 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Abdominal Fat</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>truSculpt rf device, therapeutic settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>truSculpt rf device, non-therapeutic settings</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>truSculpt rf device</intervention_name>
    <description>radiofrequency device</description>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or Male, 24 to 60 years of age (inclusive). Fitzpatrick Skin Type I - VI. Has
             visible fat bulges on the abdomen and palpable fat pockets superior to iliac crest
             located bilaterally in the lower back flank region Has a Body Mass Index (BMI) ≥ 20
             and ≤ 30 Non-smoking for at least 6 months and willing to refrain from smoking for
             the duration of the study.

        Subject must agree to not undergo any other procedure(s) in the abdominal and flank region
        during the study period.

        Subject must be able to read, understand and sign the Informed Consent Form. Subject must
        adhere to the follow-up schedule and study instructions. Subject must adhere to the same
        diet and/or exercise routine throughout the study, and agree to maintain the same weight
        throughout the study, within 5% of baseline weight measurement.

        Willing to have digital photographs taken of the treatment area and agree to use of
        photographs for presentation, educational or marketing purposes.

        Post-menopausal or surgically sterilized, or using a medically acceptable form of birth
        control at least 3 months prior to enrollment and during the entire course of the study,
        and no plans to become pregnant.

        Exclusion Criteria:

          -  Participation in a clinical trial of another device or drug within 6 months of study
             participation, or during the study period.

        Any type of prior cosmetic treatment to the target area within 12 months of study
        participation e.g., radiofrequency, cryolysis or light-based treatments.

        Any prior invasive cosmetic surgery to the target area, such as liposuction. Currently
        taking medications or supplements for weight-loss or metabolism support/enhancement or has
        a history of taking such medications or supplements within 3 months.

        Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve
        stimulator implant, cochlear implant or any other electronically, magnetically or
        mechanically activated implant.

        Has metal implant(s) within the body, such as surgical clips, plates and screws,
        intrauterine device (IUD), artificial heart valves or artificial joints.

        Significant concurrent illness, such as diabetes mellitus, cardiovascular disease,
        peripheral vascular disease or pertinent neurological disorders.

        Diagnosed or documented immune system disorders. History of any disease or condition that
        could impair wound healing. History of diseases stimulated by heat, such as recurrent
        herpes zoster in the treatment area, unless treatment is conducted following a
        prophylactic regimen.

        History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.

        Infection, dermatitis, rash or other skin abnormality in the target area. Currently
        undergoing systemic chemotherapy or radiation treatment for cancer, or history of
        treatment in the target area within 3 months of study participation.

        Pregnant or currently breastfeeding. As per the Investigator's discretion, any physical or
        mental condition which might make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>August 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
